Oramed Pharmaceuticals (Oramed Pharmaceuticals) EBIT : $3.05 Mil (TTM As of Dec. 2023)

View and export this data going back to 2007. Start your Free Trial

What is Oramed Pharmaceuticals EBIT?

Oramed Pharmaceuticals's earnings before interest and taxes (EBIT) for the three months ended in Dec. 2023 was $14.51 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Dec. 2023 was $3.05 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Oramed Pharmaceuticals's annualized ROC % for the quarter that ended in Dec. 2023 was -12.92%. Oramed Pharmaceuticals's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was 3,562.19%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Oramed Pharmaceuticals's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was -28.38%.

Oramed Pharmaceuticals EBIT Historical Data

The historical data trend for Oramed Pharmaceuticals's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Oramed Pharmaceuticals EBIT Chart

Oramed Pharmaceuticals Annual Data

Trend

Aug14

Aug15

Aug16

Aug17

Aug18

Aug19

Aug20

Aug21

Dec22

Dec23

EBIT

Get a 7-Day Free Trial

-14.63

-11.76

-24.22

-37.66

7.13

Oramed Pharmaceuticals Quarterly Data
	Feb19	May19	Aug19	Nov19	Feb20	May20	Aug20	Nov20	Feb21	May21	Aug21	Nov21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
EBIT	Get a 7-Day Free Trial															-8.74	-5.21	-3.79	-2.46	14.51

Competitive Comparison of Oramed Pharmaceuticals's EBIT

For the Biotechnology subindustry, Oramed Pharmaceuticals's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Oramed Pharmaceuticals's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Oramed Pharmaceuticals's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Oramed Pharmaceuticals's EV-to-EBIT falls into.

Oramed Pharmaceuticals EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $3.05 Mil.

Oramed Pharmaceuticals (NAS:ORMP) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Oramed Pharmaceuticals's annualized ROC % for the quarter that ended in Dec. 2023 is calculated as:

	ROC % (Q: Dec. 2023 )
=	NOPAT	/	Average Invested Capital
=	Operating Income * ( 1 - Tax Rate % )	/	( (Invested Capital (Q: Sep. 2023 )	+	Invested Capital (Q: Dec. 2023 ))	/ count )
=	-15.508 * ( 1 - 0% )	/	( (130.802	+	109.247)	/ 2 )
=	-15.508	/	120.0245
=	-12.92 %

where

	Invested Capital		(Q: Sep. 2023 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	230.893	-	2.561	-	( 175.039	-	max(0, 78.175	-	175.705	+	175.039	))
=	130.802

	Invested Capital		(Q: Dec. 2023 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	220.551	-	1.934	-	( 162.047	-	max(0, 53.214	-	162.584	+	162.047	))
=	109.247

Note: The Operating Income data used here is four times the quarterly (Dec. 2023) data.

2. Joel Greenblatt's definition of Return on Capital:

Oramed Pharmaceuticals's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2023 is calculated as:

	ROC (Joel Greenblatt) %		(Q: Dec. 2023 )
=	EBIT	/	Average of (Net fixed Assets	+	Net Working Capital)
=	EBIT	/	Average of (Property, Plant and Equipment	+	Net Working Capital)
			Q: Sep. 2023		Q: Dec. 2023
=	EBIT	/	( ( (Property, Plant and Equipment + Net Working Capital)	+	(Property, Plant and Equipment + Net Working Capital) )	/	count )
=	58.028	/	( ( (1.691 + max(-1.895, 0))	+	(1.567 + max(-1.397, 0)) )	/	2 )
=	58.028	/	( ( 1.691	+	1.567 )	/	2 )
=	58.028	/	1.629
=	3,562.19 %

where Working Capital is:

	Working Capital		(Q: Sep. 2023 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(0	+	0	+	0.66600000000003)	-	(2.561	+	0	+	-1.4210854715202E-14)
=	-1.895

	Working Capital		(Q: Dec. 2023 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(0	+	0	+	0.53700000000001)	-	(1.934	+	0	+	0)
=	-1.397

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Dec. 2023) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Oramed Pharmaceuticals's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %	=	EBIT (TTM)	/	Enterprise Value (Q: Dec. 2023 )
	=	3.05	/	-10.748
	=	-28.38 %

Oramed Pharmaceuticals EBIT Related Terms

Thank you for viewing the detailed overview of Oramed Pharmaceuticals's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Oramed Pharmaceuticals (Oramed Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Oramed Pharmaceuticals Inc (NAS:ORMP) » Definitions » EBIT

Comparable Companies

Traded in Other Exchanges

OJU1:Germany

Address

1185 Avenue of the Americas, Third Floor, New York, NY, USA, 10036

Website

https://www.oramed.com

Oramed Pharmaceuticals Inc is a pharmaceutical company which is engaged in the research and development of pharmaceutical solutions, including an oral insulin capsule to be used for the treatment of individuals with diabetes, and the use of orally ingestible capsules or pills for delivery of other polypeptides. The ORMD-0801 is a proprietary product which is an orally ingestible insulin capsule for the treatment of diabetes. Its other product includes Oral Glucagon-like peptide-1 which is an incretin hormone, a type of gastrointestinal hormone that stimulates the secretion of insulin from the pancreas.

Executives

Benjamin Shapiro	director	1185 AVENUE OF THE AMERICAS, 3RD FLOOR, NEW YORK NY 10036
Nadav Kidron	director, 10 percent owner	142 W. 57TH ST., NEW YORK NY 10019
Yadin Rozov	director	9 TERRACE CIRCLE, ARMONK NY 10504
Miriam Kidron	director	2 ELZA STREET, JERUSALEM L3 93706
Michael Rabinowitz	officer: Chief Commercial Officer	1185 AVENUE OF THE AMERICAS, THIRD FLOOR, NEW YORK NY 10036
Arie Mayer	director	MORAN 16, KFAR SABA L3 4428890
Netanel Derovan	officer: Chief Legal Officer	1185 AVENUE OF THE AMERICAS, 3RD FLOOR, NEW YORK NY 10036
David Silberman	officer: Chief Financial Officer	20 MAMILLA AVENUE, JERUSALEM L3 9414904
Kevin Rakin	director	36 CHURCH LANE, WESTPORT CT 06880
Michael Rabinowitz	officer: Chief Commercial Officer	MAXIM GROUP, LLC, 405 LEXINGTON AVENUE, NEW YORK NY 10174
Leonard Sank	director	3 BLAIR ROAD, CAPE TOWN T3 8005
Gao Xiaoming	director	11F. NO. 266 HANKOU ROAD, HUANGPU DISTRICT, SHANGHAI F4 2000001
Avraham Gabay	officer: CFO, Treasurer and Secretary	2/4 HIGH-TECH PARK, P.O. BOX 39098, JERUSALEM L3 91390
Mark Daniel Hasleton	officer: VP Business Development	13, HIBAT ZION, RAANANA, RAANANA L3 4338111
Aviad Friedman	director	HADASSA 6, TEL AVIV L3 6451306